Tenax Therapeutics (TENX) Competitors $5.93 +0.01 (+0.17%) Closing price 03:58 PM EasternExtended Trading$5.93 0.00 (0.00%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. BMEA, ANEB, MGNX, SAVA, TCRX, ANRO, SPRO, HLVX, CNTB, and SKYEShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Cassava Sciences (SAVA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), Spero Therapeutics (SPRO), HilleVax (HLVX), Connect Biopharma (CNTB), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Biomea Fusion Anebulo Pharmaceuticals MacroGenics Cassava Sciences TScan Therapeutics Alto Neuroscience Spero Therapeutics HilleVax Connect Biopharma Skye Bioscience Tenax Therapeutics (NASDAQ:TENX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Which has higher valuation & earnings, TENX or BMEA? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$0.92-6.45Biomea FusionN/AN/A-$138.43M-$3.03-0.63 Does the media favor TENX or BMEA? In the previous week, Biomea Fusion had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Biomea Fusion and 2 mentions for Tenax Therapeutics. Biomea Fusion's average media sentiment score of 0.96 beat Tenax Therapeutics' score of 0.93 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TENX or BMEA? Tenax Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Is TENX or BMEA more profitable? Tenax Therapeutics' return on equity of -31.34% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.34% -30.39% Biomea Fusion N/A -243.95%-140.74% Do institutionals & insiders have more ownership in TENX or BMEA? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Comparatively, 18.4% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer TENX or BMEA? Tenax Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 186.68%. Biomea Fusion has a consensus price target of $15.73, suggesting a potential upside of 719.13%. Given Biomea Fusion's higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.15 SummaryBiomea Fusion beats Tenax Therapeutics on 8 of the 14 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.01M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-6.4521.0831.2626.59Price / SalesN/A400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book0.268.0910.046.68Net Income-$17.60M-$54.08M$3.27B$265.59M7 Day Performance-1.82%2.25%3.17%3.42%1 Month Performance-3.58%3.41%4.34%1.09%1 Year Performance53.23%18.61%44.12%23.84% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.4958 of 5 stars$5.93+0.2%$17.00+186.7%+48.0%$27.01MN/A-6.459BMEABiomea Fusion3.6801 of 5 stars$1.81-1.1%$16.80+828.2%-76.3%$108.90MN/A-0.6050Analyst ForecastGap UpANEBAnebulo Pharmaceuticals2.3651 of 5 stars$2.70+3.8%$5.50+103.7%+28.6%$106.82MN/A-10.384Positive NewsMGNXMacroGenics4.3767 of 5 stars$1.64-3.0%$3.60+119.5%-49.9%$106.82M$149.96M-2.88430SAVACassava Sciences1.7376 of 5 stars$2.16-1.8%$2.00-7.4%-92.0%$106.28MN/A-0.8530TCRXTScan Therapeutics3.1763 of 5 stars$1.90+1.6%$7.80+310.5%-66.2%$106.12M$2.82M-1.74100ANROAlto Neuroscience1.6494 of 5 stars$3.93+0.8%$8.50+116.3%-65.0%$105.60MN/A-1.64N/ATrending NewsSPROSpero Therapeutics4.0686 of 5 stars$1.85-1.1%$5.00+170.3%+43.5%$105.24M$47.98M-1.89150Positive NewsHLVXHilleVax1.7295 of 5 stars$2.12+2.9%$2.00-5.7%+7.8%$103.29MN/A-1.4820Positive NewsCNTBConnect Biopharma3.3479 of 5 stars$1.87+2.2%$7.00+274.3%+77.7%$101.97M$1.97M0.00110Positive NewsGap UpSKYESkye Bioscience1.6363 of 5 stars$3.54+7.6%$15.50+337.9%-44.2%$101.95MN/A-3.3411Gap Up Related Companies and Tools Related Companies Biomea Fusion Alternatives Anebulo Pharmaceuticals Alternatives MacroGenics Alternatives Cassava Sciences Alternatives TScan Therapeutics Alternatives Alto Neuroscience Alternatives Spero Therapeutics Alternatives HilleVax Alternatives Connect Biopharma Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access